PT - JOURNAL ARTICLE AU - Laise de Moraes AU - Luciane Amorim Santos AU - Liã Bárbara Arruda AU - Maria da Purificação Pereira da Silva AU - Márcio de Oliveira Silva AU - José Adriano Góes Silva AU - André Ramos AU - Marcos Bastos dos Santos AU - Felipe Guimarães Torres AU - Cibele Orge AU - Antonio Marcos Teixeira AU - Thiago Vieira AU - Laura Ramírez AU - Manuel Soto AU - Maria Fernanda Rios Grassi AU - Isadora Cristina de Siqueira AU - Dorcas Lamounier Costa AU - Carlos Henrique Costa AU - Bruno de Bezerril Andrade AU - Kevan Akrami AU - Camila Indiani de Oliveira AU - Viviane Sampaio Boaventura AU - Manoel Barral-Netto AU - Aldina Barral AU - Anne-Mieke Vandamme AU - Johan Van Weyenbergh AU - Ricardo Khouri TI - High seroprevalence of <em>Leishmania infantum</em> is linked to immune activation in people with HIV: a two-stage cross-sectional study in Bahia, Brazil AID - 10.1101/2021.10.03.21264311 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.03.21264311 4099 - http://medrxiv.org/content/early/2021/10/04/2021.10.03.21264311.short 4100 - http://medrxiv.org/content/early/2021/10/04/2021.10.03.21264311.full AB - Background Visceral leishmaniasis is an opportunistic disease in HIV-1 infected individuals, although not yet recognized as a determining factor for AIDS diagnosis. The growing geographical overlap of HIV-1 and Leishmania infections is an emerging challenge worldwide, as co-infection increases morbidity and mortality for both. Here, we determined the prevalence of people living with HIV (PWH) with a previous or ongoing infection by Leishmania infantum in Bahia, Brazil and investigated the virological and immunological factors associated with co-infection.Methodology and Principal Findings We adopted a two-stage cross-sectional cohort (CSC) design (CSC-I, n=5,346 and CSC-II, n=317) of treatment-naïve HIV-1-infected individuals in Bahia, Brazil. In CSC-I, samples collected at the time of HIV-1 diagnosis between 1998 and 2013 were used for serological screening for leishmaniasis by an in-house immunoassay (ELISA) with SLA (Soluble Leishmania Antigen), resulting in a prevalence of previous or ongoing infection of 16.27%. Next, 317 PWH were prospectively recruited from July 2014 to December 2015 with collection of sociodemographic and clinical data. Serological validation by two different immunoassays confirmed a prevalence of 15.46% and 8.20% by anti-SLA, and anti-HSP70 serology, respectively, whereas 4.73% were double-positive (DP). Stratification of these 317 individuals in DP and double-negative (DN) revealed a significant reduction of CD4+ counts and CD4+/CD8+ ratios and a tendency of increased viral load in the DP group, as compared to DN. No statistical differences in HIV-1 subtype distribution were observed between the two groups. However, we found a significant increase of CXCL10/IP-10 (p=0.0076) and a tendency of increased CXCL9/MIG (p=0.061) in individuals with DP serology for L. infantum, demonstrating intensified immune activation in this group. These findings were corroborated at the transcriptome level in independent Leishmania- and HIV-1-infected cohorts (Swiss HIV Cohort and Piaui Northeast Brazil Cohort), indicating that CXCL10 transcripts are shared by the IFN-dominated immune activation gene signatures of both pathogens and positively correlated to viral load in untreated PWH.Conclusions/Significance This study demonstrated a high prevalence of PWH with L. infantum seropositivity in Bahia, Brazil, linked to IFN-mediated immune activation and a significant decrease in CD4+ levels. Our results highlight the urgent need to increase awareness and define public health strategies for the management and prevention of HIV-1 and L. infantum co-infection.AUTHOR SUMMARY More than 1 billion people live in areas endemic for leishmaniasis and are at risk of infection, which includes one third of the 38 million people living with HIV (PWH) worldwide. Leishmaniasis is a neglected tropical disease caused by infection with Leishmania parasites, transmitted by bites from infected sand flies. HIV/Leishmania co-infection is increasing worldwide, especially in Southern Europe and Brazil, due to both human and ecological factors (migration, climate change, deforestation). This study demonstrates that a worryingly high number (one out of 6) of PWH in Bahia (Northeast Brazil) show previous or ongoing infection with the parasite Leishmania infantum, determined by antibodies detection against this parasite in PWH. Using a rigorous study design with data collection over 18 years in &gt;5500 PWH, we found similarly high numbers (16.3% and 15.5%) of PWH with antibodies against Leishmania infantum in two consecutive cohorts. Moreover, PWH with antibodies against Leishmania infantum in Bahia, Brazil displayed a worse immune profile, with lower CD4 immune cells numbers and immune activation mediated by interferon, which we confirmed in independent HIV- and Leishmania-infected cohorts from other geographic areas. Our results underscore the need to raise awareness and define public health strategies to prevent HIV/Leishmania co-infection, since therapeutic failure and mortality are strongly increased in co-infected PWH, even with antiretroviral therapy as standard of care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financed in part by Fundação de Amparo á Pesquisa do Estado da Bahia (FAPESB, APP0032/2016), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES – finance code 001) and FWO (grant G0D6817N). None of the funding organizations had any role in the study design, data collection, data interpretation or writing of this report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted following the Declaration of Helsinki and was approved by the Institutional Review Board of the Gonçalo Moniz Institute (IGM-FIOCRUZ) (protocol number 1.764.505).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study are available within the article and its supplementary materials.